How to buy Neuren Pharmaceuticals shares | A$1.095
Own Neuren Pharmaceuticals shares in just a few minutes.
We’re committed to our readers and editorial independence. We don’t compare all products in the market and may receive compensation when we refer you to our partners, but this does not influence our opinions or reviews. Learn more about Finder .
Neuren Pharmaceuticals Limited is a biotechnology business based in Australia. Neuren Pharmaceuticals shares (NEU) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $1.095 – a decrease of 1.35% over the previous week. Neuren Pharmaceuticals has a trailing 12-month revenue of around $545,000.
How to buy shares in Neuren Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Neuren Pharmaceuticals . Find the share by name or ticker symbol: NEU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neuren Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $1.095, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Neuren Pharmaceuticals . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
🧪How we chose these brokersFor our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.
What's in this guide?
- Neuren Pharmaceuticals key stats
- Compare share trading platforms
- Is Neuren Pharmaceuticals stock a buy or sell?
- Neuren Pharmaceuticals performance over time
- Neuren Pharmaceuticals 's financials
- How volatile are Neuren Pharmaceuticals shares?
- Does Neuren Pharmaceuticals pay a dividend?
- Have Neuren Pharmaceuticals shares ever split?
- Other common questions
How has coronavirus impacted Neuren Pharmaceuticals 's share price?
Since the stock market crash in March caused by coronavirus, Neuren Pharmaceuticals 's share price has had significant negative movement.
Its last market close was $1.095, which is 60.04% down on its pre-crash value of $2.74 and 13.47% up on the lowest point reached during the March crash when the shares fell as low as $0.965.
If you had bought $1,000 worth of Neuren Pharmaceuticals shares at the start of February 2020, those shares would have been worth $406.59 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $401.10.
Neuren Pharmaceuticals share priceUse our graph to track the performance of NEU stocks over time.
Neuren Pharmaceuticals shares at a glance
|Latest market close||AUDA$1.095|
|52-week range||AUDA$0.965 - AUDA$3.04|
|50-day moving average||AUDA$1.1742|
|200-day moving average||AUDA$1.3693|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.007|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Neuren Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Neuren Pharmaceuticals price performance over time
|1 week (2020-10-10)||N/A|
|1 month (2020-09-21)||-6.41%|
|3 months (2020-07-17)||-9.50%|
|6 months (2020-04-17)||-36.89%|
|1 year (2019-10-18)||-56.72%|
|2 years (2018-10-19)||-12.75%|
|3 years (2017-10-19)||-56.20%|
|5 years (2015-10-19)||-44.70%|
Is Neuren Pharmaceuticals under- or over-valued?
Valuing Neuren Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neuren Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neuren Pharmaceuticals 's EBITDA
Neuren Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.8 million.
The EBITDA is a measure of a Neuren Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.
Neuren Pharmaceuticals financials
|Gross profit TTM||$-9,363,000|
|Return on assets TTM||-37.93%|
|Return on equity TTM||-59.46%|
|Market capitalisation||$136.5 million|
TTM: trailing 12 months
Neuren Pharmaceuticals share dividends
We're not expecting Neuren Pharmaceuticals to pay a dividend over the next 12 months.
Have Neuren Pharmaceuticals 's shares ever split?
Neuren Pharmaceuticals 's shares were split on a 1:20 basis on 20 November 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neuren Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Neuren Pharmaceuticals shares which in turn could have impacted Neuren Pharmaceuticals 's share price.
Neuren Pharmaceuticals share price volatility
Over the last 12 months, Neuren Pharmaceuticals 's shares have ranged in value from as little as $0.965 up to $3.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Neuren Pharmaceuticals 's is 1.2069. This would suggest that Neuren Pharmaceuticals 's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Neuren Pharmaceuticals overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.
Frequently asked questions
Ask an Expert